

MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS



EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease:

A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
 2. Blood vessels, Surgery.
-
- I. Fitridge, Robert
 - II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters
Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre
Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1
Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)
2. Vascular smooth muscle structure and function 13
David Wilson (Adelaide, Australia)
3. Atherosclerosis 25
Gillian Cockerill, Qingbo Xu (London, UK)
4. Mechanisms of plaque rupture 43
Ian Loftus (London, UK)
5. Current and emerging therapies in atheroprotection 79
Stephen Nicholls, Rishi Puri (Cleveland, USA)
6. Molecular approaches to revascularisation in peripheral vascular disease 103
Greg McMahon, Mark McCarthy (Leicester, UK)
7. Biology of restenosis and targets for intervention 115
Richard Kenagy (Seattle, USA)
8. Vascular arterial haemodynamics 153
Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)
9. Physiological haemostasis 177
Simon McRae (Adelaide, Australia)
10. Hypercoagulable states 189
Simon McRae (Adelaide, Australia)
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201
Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)
12. Pathogenesis of aortic aneurysms 227
Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)
13. Pharmacological treatment of aneurysms 247
Matthew Thompson, Janet Powell (London, UK)
14. Aortic dissection and connective tissue disorders 255
Mark Hamilton (Adelaide, Australia)
15. Biomarkers in vascular disease 277
Ian Nordon, Robert Hincliffe (London, UK)
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295
Martin Veller (Johannesburg, South Africa)
17. SIRS, sepsis and multiorgan failure 315
Vishwanath Biradar, John Moran (Adelaide, Australia)
18. Pathophysiology of reperfusion injury 331
Prue Cowled, Robert Fitridge (Adelaide, Australia)
19. Compartment syndrome 351
Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)
20. Pathophysiology of pain 375
Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)

21. Postamputation pain 389
Stephan Schug, Gail Gillespie
(Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard
(Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin,
Lyle Moldauer, Robert Diegelmann
(Florida, USA)
 24. Pathophysiology and principles of
varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg
ulceration: Principles and vascular
biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of
management of the diabetic foot 475
David Armstrong, Timothy Fisher,
Brian Lepow, Matthew White,
Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics
and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton
(London, UK)
 29. Pathophysiology of vascular graft
infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular Ca^{2+}
- Sources of cytosolic Ca^{2+} entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction	43
Evidence for the ‘plaque rupture theory’	44
Coronary circulation	
Cerebral circulation	
The role of individual components of the arterial wall	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
The role of angiogenesis in plaque rupture	
The role of infectious agents in plaque rupture	57
Risk prediction of plaque instability	58
Imaging	
Blood markers	59
Therapy aimed at plaque stabilisation	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
Summary	62
References	63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background	79
Pathology	
Risk factor modification	80
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
Risk factor modification in the diabetic patient	89
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
Future targets	93
Conclusion	
References	94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction	103
Mechanisms of vascular growth	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
Therapeutic induction of vascular growth	107
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
Conclusions	110
References	

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

CHAPTER 10 – HYPERCOAGULABLE STATES

Simon McRae

Introduction 189

Classification of thrombophilia

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

Potential detrimental effects of thrombophilia testing 197

Conclusion

References

CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter*

Introduction 201

Platelet function – Adhesion and activation

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

Platelet function testing 215

Light-transmission aggregometry

Whole blood aggregometry 217
 VerifyNow® Assay
 Flow cytometry 218

References

CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,
 Paul E Norman*

Introduction 227

Differences between thoracic and abdominal aortic aneurysms 228

Summary of current theories and stages of AAA evolution

Atherosclerosis and AAA

Immune mechanisms in AAA 229

Extracellular matrix dysfunction 232

Infection 233

Biomechanical forces

Angiogenesis

Intra-luminal thrombus

Extracellular matrix proteolysis 234

Genetics 236

AAA rupture 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

Future research

References

CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

Matthew Thompson, Janet T Powell

Background 247

Screening programmes

Pathophysiology 248

Therapeutic strategies

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

Drugs acting on the renin/angiotensin axis

HMG Co-A reductase inhibitors 251

The future – Data from recent

experimental studies

References

CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

Mark Hamilton

Introduction 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

Classification of aortic syndromes

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

Pathogenesis of thoracic aortic dissection

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

Complications of acute aortic syndromes 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

Connective tissue disorders and acute aortic syndromes

Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	268
Loeys-Deitz syndrome	270
Familial thoracic aortic aneurysm disease	271
Bicuspid aortic valve	273
Turners Syndrome	
Summary	274
Reference list	

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction	277
What is a biomarker?	
Types of biomarkers	
A classical clinical example	278
Potential value of biomarkers in vascular disease	279
Biomarker discovery steps	280
AAA biomarkers	
Circulating extracellular matrix markers	281
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
Biomarkers of AAA rupture	285
Biomarkers following endovascular repair	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
Challenges in biomarkers discovery	
Future work	
Conclusion	289
References	

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides	295
Introduction	
Classification of vasculitides	296
Clinical presentation of vasculitides	
Investigations of vasculitides	
Principles of treatment of vasculitides	297
The vasculitides of specific interest to vascular surgeons	298
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
Pathophysiology and principles of Raynaud's phenomenon	307
Prevalence of Raynaud's phenomenon	308
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
Prognosis	310
Treatment	
Recommendations	311
References	312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multorgan dysfunction syndrome (MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 –
PATHOPHYSIOLOGY OF
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain components 396

Neuropharmacological therapies

Invasive therapies
 Electroconvulsive therapy (ECT)
 Nerve blockade
 Spinal cord stimulation
 Implantable intrathecal delivery systems
 Dorsal root entry zone (DREZ) lesions
 Psychological therapy 397

Future aims

References

CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN

Stephan Schug, Kathryn Stannard

Introduction 401

Principles of treatment

Pharmacological treatment 402

Opioids

Recommendations for clinical use of opioids

Tramadol

Mechanism of action

Efficacy 403

Adverse effects

Recommendations for clinical use of tramadol in neuropathic pain

Antidepressants

Tricyclic antidepressants (TCAs)

Mechanism of action 404

Adverse effects

Selective serotonin re-uptake inhibitors (SSRIs)

Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405

Recommendations for clinical use of antidepressants as analgesics

Anticonvulsants

Mechanism of action 406

Individual medications

Clonazepam

Gabapentin

Pregabalin 407

Carbamazepine

Sodium valproate 408

Phenytoin

Lamotrigene

Recommendations for clinical use of anticonvulsants as analgesics

Local anaesthetics and antiarrhythmics 409

Mechanism of action

Lignocaine

Mexiletine

Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain

N-methyl-D-aspartate-receptor antagonists (NMDA)

Ketamine 410

Other NMDA antagonists

Miscellaneous compounds for systemic use

Clonidine

Efficacy

Baclofen

Levodopa 411

Cannabinoids

Topical treatments

Lignocaine 5% medicated plaster

Capsaicin 412

Mechanism of action

Efficacy

Non-pharmacological therapy

Transcutaneous electrical nerve stimulation (TENS)

Spinal cord stimulation (SCS) 413

Sympathetic nerve blocks

Neurosurgical destructive techniques

Cognitive behaviour therapy

References 414

CHAPTER 23 – PRINCIPLES OF WOUND HEALING

Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann

Introduction 423

Phases of acute wound healing

Haemostasis

- Inflammation 426
 - Neutrophils 427
 - Macrophages 428
- Proliferative phase 429
 - Fibroblast migration 430
 - Collagen and extracellular matrix production
 - Angiogenesis 431
 - Granulation 432
 - Epithelialization
 - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
 - Normal and pathological responses to injury
 - Biochemical differences in the molecular environments of healing and chronic wounds 436
 - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
 - Role of endocrine hormones in the regulation of wound healing
 - Molecular basis of chronic non-healing wounds
 - Chronic venous stasis ulcers 441
 - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
 - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

Andrew Bradbury

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
 - New varicose veins
 - Persistent varicose veins
 - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

Michael Stacey

- Definitions 459**
 - Chronic venous insufficiency
 - Leg ulceration
 - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
 - Venous abnormality
 - Effect of ambulatory venous hypertension on the tissues in the leg 463
 - Influence of venous disease on the wound healing process 465
 - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
 - Compression therapy
 - Dressings 468
 - Surgery
 - Prevention of venous ulcer recurrence 470
 - Sclerotherapy and other techniques to obliterate surface and perforating veins
 - Other therapies 471
- References**

CHAPTER 26 –
PATHOPHYSIOLOGY AND
PRINCIPLES OF MANAGEMENT
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
 - Structural abnormalities/gait abnormalities
 - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
 - Neurological examination 479
 - Monofilament testing
 - Vibration testing
 - Dermatologic examination 480
 - Anatomy of occlusive disease – vascular examination
 - Prediction of wound healing: assessment of perfusion 481
 - Arterial imaging
 - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
 - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
 - Epidemiology and risk factors
 - Offloading
 - Non-vascular surgical treatment 485
 - Class I – Elective 486
 - Class II – Prophylactic
 - Class III – Curative
 - Class IV – Emergency (urgent)
 - Post-operative management
 - Infections 487
 - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA
– PRINCIPLES, GENETICS AND
PATHOPHYSIOLOGY

Matt Waltham

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
 - Lymphoedema – distichiasis syndrome 501
 - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
 - Meige disease (primary non-syndromic lymphoedema)
 - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT
MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
 - Healing of prosthetic grafts 512
 - The healing process of the anastomosis
 - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
 - Anastomotic compliance mismatch
 - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
 - Modifications and newer developments of PTFE grafts 517
 - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
Prosthetic graft modifications	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
Endothelial cell seeding	522
Single stage seeding	
Two stage seeding	
Vascular tissue engineering	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
Graft materials for aortic endografts	526
The future	
References	527

CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

Mauro Vicaretti

Introduction	537
Natural history of prosthetic vascular graft infections	
Mechanism of graft contamination at operation	538
Pathogenesis of graft infections	
Bacteriology of vascular graft infections	
Investigations for detection of prosthetic graft infections	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
Management of prosthetic graft infections	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
Established infection	
Antibiotic therapy	
Operative management	
Conclusion	542
References	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

26 • Pathophysiology and Principles of Management of the Diabetic Foot

¹DAVID G. ARMSTRONG, ²TIMOTHY K. FISHER,
¹BRIAN LEPOW, ⁴MATTHEW L. WHITE, ^{1,4}JOSEPH L. MILLS.

¹The University of Arizona, Southern Arizona Limb Salvage Alliance (SALSA), Tucson, Arizona, USA

²Rashid Centre for Diabetes and Research, Sheikh Khalifa Hospital, Ajman, UAE

³Vascular and Endovascular Surgery, University of Arizona, Tucson, Arizona, USA

INTRODUCTION

The incidence of diabetes continues to grow at a staggering pace. The United States' Centers for Disease Control and Prevention estimate that 23.6 million people or 7.8% of the U.S. population has diabetes, with 1.6 million new cases being diagnosed each year.^{1,2} These figures are even more astonishing when one considers worldwide estimates. Close to 4 million deaths in the 20–79 year old age group may be attributed to diabetes in 2010, accounting for 6.8% of global all-cause mortality in this age group.³ The number of people with diabetes worldwide is expected to reach 366 million people by 2030, more than double the estimated 177 million people affected with the disease in 2000.² The increased disease prevalence is accompanied by an increase in associated comorbidities. The literature estimates that patients with diabetes have nearly a 25% lifetime risk of developing a foot ulcer with more than 50% of these ulcers becoming infected and requiring

hospitalization.⁴ In fact, at least 20% of all diabetes-related hospital admissions are due to diabetic foot ulcers. Associated with foot ulcers and infection is the incidence of amputation. It has been conservatively reported that, worldwide, a major amputation takes place every 30 seconds with over 2500 limbs lost per day.⁵ At least 60% of all non-traumatic lower extremity amputations are related to complications of diabetes.¹ People with diabetes who have had one amputation have a 68% risk of having another in the next 5 years and have a 50% mortality rate in the 5 years following the initial amputation.⁶ It is estimated that up to 85% of diabetic foot-related amputations could be prevented through prompt intervention and with centers directed at educating individuals about proper foot care.

The economic impacts on the patient, national healthcare system and economy also impose a great burden. Healthcare expenditures on diabetes are expected to account for 11.6% of the total healthcare

expenditure in the world in 2010.³ The estimated global costs to treat and prevent diabetes and its complications are expected to total at least 376 billion USD in 2010, with some projections exceeding 490 billion USD. Between 22 and 27% of the total diabetes costs are attributable to lower extremity disease.^{3,7}

PATHOPHYSIOLOGY OF THE DIABETIC FOOT

Neuropathy

Neuropathy, or the loss of protective sensation (LOPS) of the lower extremity, is the predominant etiology for diabetic foot ulceration. The absence of this most basic nociceptive mechanism results in the patient's inability to perceive local foot trauma both from intrinsic factors such as abnormal or faulty foot mechanics or deformity, as well as extrinsic factors such as foreign objects or improper footwear. These factors place the foot at increased risk for developing an ulcer, which can lead to amputation.

Neuropathy can be subdivided into sensory, motor, and autonomic categories.

Sensory neuropathy typically begins distally, moving proximally, and is symmetrical. It is often described as a 'stocking-glove' distribution.

Motor neuropathy results in intrinsic muscle wasting, causing a progressive deformity such as hammertoe, claw toe, and plantar flexion deformities of the metatarsals. These deformities can cause an increase in focal pressure at the areas of the interphalangeal joints of the digits and beneath the metatarsal heads, respectively, increasing the probability of ulcer formation.

Autonomic neuropathy is associated with pathology of the sympathetic nervous system. In the lower extremity, this usually results

in the absence of sweat production causing drying and scaling of the skin, increasing the likelihood of cracking and fissuring. These cracks or fissures, especially in the heel, may then serve as a portal of entry for bacteria, creating an increased chance of infection.

Other factors precipitating diabetic foot ulcers have been identified and are listed in Table 26.1. A risk factor classification scheme has been developed based on LOPS and other comorbidities (i.e. vascular disease) (Table 26.2). This classification system provides treatment recommendations and suggested follow-up time.

Structural abnormalities/gait abnormalities

Structural deformities of the foot and ankle can be a potential cause of increased pressure and subsequent ulceration. The development of foot ulceration is often based on a biomechanical abnormality.^{8,9} It is important to evaluate both feet of a patient for any potential problem areas. As described earlier, motor neuropathy can lead to the loss of intrinsic foot musculature causing a deformity (and subsequent overpowering of the intrinsics by the larger extrinsic muscles). Identification and management of any of the following will assist in prevention of potential ulceration: hammertoe, claw toe, bunion, tailor's bunion (bunionette), hallux limitus/rigidus, flat feet, high arched feet, Charcot deformities, or any postsurgical deformities such as amputations. Limited joint mobility should also be evaluated as it can cause an increase in vertical and shear force in certain areas, particularly to the plantar hallux, and lead to tissue breakdown. The Achilles tendon should be evaluated for any type of functional shortening causing equinus deformity. It is common to find an increase in glycosylation of soft tissues and tendons causing contracture of the muscles in the

TABLE 26.1: Risk Factors For Ulceration

General or Systemic Factors	Local Factors
<ul style="list-style-type: none"> • Uncontrolled Hyperglycemia • Duration of Diabetes • Peripheral Vascular Disease • Older Age • Chronic Renal Disease • Blindness or visual loss 	<ul style="list-style-type: none"> • Peripheral Neuropathy • Structural Foot Deformity • Limited Joint Range of Motion • Trauma • Improperly fitted shoes • Callus • Prolonged Elevated Focal Pressure • History of Previous Ulcer or Amputation

TABLE 26.2a: American Diabetes Association Risk Classification for The Diabetic Foot.

Risk Category	Definition	Treatment Recommendations	Suggested Follow-Up
0	No LOPS, no PAD, no deformity	– Patient education including advice on appropriate footwear	Annually (by podiatrist)
1	LOPS ± deformity	– Consider prescriptive or accommodative footwear – Consider prophylactic surgery if deformity cannot be safely accommodated in shoes. Continue patient education	Every 3–6 months (by podiatrist +/- specialist)
2	PAD ± LOPS	– Consider prescriptive or accommodative footwear – Consider vascular consultation for combined follow-up	Every 2–3 months (by podiatrist +/- vascular surgeon)
3	History of ulcer or amputation	– Same as category 1 – Consider vascular consultation for combined follow-up if PAD present	Every 1–2 months –(by podiatrist)

TABLE 26.2b: The University of Texas (UT) Wound Classification System

UT System		
Grade	Description	Stage
1	Pre- or post ulcerative lesion	A–D
2	Superficial	A–D
3	Penetrated to tendon or capsule	A–D
4	Penetrates to bone	A–D

Stages: A = no infection or ischemia; B = infection; C = ischemia; D = infection and ischemia

posterior compartment of the leg.¹⁰⁻¹² This will cause an increase in plantar pressures in the forefoot making this area more prone to breakdown.

Gait evaluation and muscle testing should also be conducted to evaluate any potential abnormality with ambulation and muscle strength. Testing of the muscles in the lower extremity should be done both actively and passively, weight bearing and non-weight bearing. Plantar foot pressures can also be assessed with the use of a Harris ink mat or pressure sensitive foot mat.

Angiopathy

In combination with the risk factors for ulceration discussed above, the presence of vascular occlusive disease increases the risk of potential amputation. Vascular disease is a common finding in individuals with long-standing diabetes. While vascular insufficiency alone is not usually the primary cause of ulceration, inadequate perfusion can inhibit ulcer healing, leading to further tissue necrosis and the inability to clear infection. Table 26.3 provides a list of other potential risk factors for amputation. Most cases of vascular disease in individuals with diabetes, interestingly, affect the infrapopliteal vessels with relative sparing of the pedal vessels. In many instances, this allows for a distal bypass to a pedal target artery in order to increase the blood flow to the foot (Figure 26.1). The vascular examination is addressed in further detail later in this chapter.

DIAGNOSIS

History and rapid visual screening

A thorough history and physical examination of each patient presenting with diabetic foot pathology should include a history of pedal wounds, history of prior amputations, and

lower extremity vascular interventions.^{13,14} Physical examination should note the types of deformities present, neurological status, vascular status, and dermatological presentation. The patient should be instructed to remove both shoes and socks for their examination. A systematic approach should be taken in order to avoid missing any

TABLE 26.3: Risk Factors for Amputation:

- Peripheral Neuropathy (LOPS)
- Vascular Insufficiency (PAD)
- Infection
- Structural Foot Deformity
- Trauma
- History of prior foot ulcer or amputation
- Charcot foot
- Poor glycaemic control
- Older age
- Male gender
- Ethnicity (higher in Hispanics and African-Americans)




FIGURE 26.1: Dorsalis Pedis Bypass

important aspects of the examination. All surfaces of the foot and ankle should be evaluated including the nails, digits, interdigital webspaces, the soles, and the heels, inspecting for cracks, blisters or bullae, hyper/hypopigmentation, fissuring, calluses, and ulcers. The footwear should also be inspected for signs of wear patterns, foreign bodies, and any irregularities. Any gross deformities as described above can be identified during this rapid visual screening.¹⁴

Neurological examination

As stated earlier, peripheral sensory neuropathy is the major risk factor for the development of a diabetic foot ulcer. There are many simple, noninvasive examinations that can be performed to test and monitor sensation. A simple history of neuropathic symptoms such as tingling, burning, numbness, the feeling of insects crawling on the feet (formication) can help to identify those patients at risk for developing foot ulceration.¹⁵

Monofilament testing

One of the most common methods used to assess neuropathy is the use of the Semmes-Weinstein monofilament (10-g) wire.^{14,15} The nylon monofilament is placed on ten different pre-determined locations on the foot and pressed down manually until there is a slight bend in the wire (Figure 26.2). The patient is instructed to say 'yes' if he or she thinks they feel slight pressure or sensation. If the patient is unable to feel the sensation at two or more locations then it is safe to assume that protective sensation is lost.

Vibration testing

Vibratory perception testing can be assessed utilizing several different modalities. The more traditional method of testing is by the

use of a 128-Hz tuning fork. The tuning fork is struck and then placed on a prominent bony surface of the foot, such as the great toe or metatarsal head. The patient is instructed to identify when the vibration stops.

As an alternative, a vibratory perception threshold monitor (VPT – Diabetica Solutions, San Antonio, Texas, USA) (Figure 26.3) can be used to test for vibration perception threshold and is useful in identifying those at high risk for development of an ulcer. The instrument consists of a hand piece with a testing probe on the end, a motor, rheostat, and voltmeter. The probe is held gently on the distal aspect of each hallux, or distal most prominent area. The rheostat is slowly increased until the patient senses the vibration. Once the patient identifies the sensation, the rheostat is then decreased until the sensation is no longer felt. The average value of the two numerical readings is taken and the level of sensation is documented to the location where the numbers were obtained. Average values above 25 Volts



FIGURE 26.2: Proper use of S-W Monofilament when applied to the foot. Slight bend of the filament noted.



FIGURE 26.3: Vibratory Perception Threshold Monitor (VBT)

are considered positive for neuropathic changes.¹⁴

Dermatologic examination

Following assessment for any loss of sensation, evaluation of the integument is a critical part of the foot screening. The skin can be evaluated for color, texture, turgor, quality, and presence of any areas of dryness or fissures. Calluses, if present, can be problematic as they indicate areas of increased pressure and an ulcer can form under the hyperkeratotic lesion, which may cause hemorrhage beneath the callus. Debridement of these areas is recommended in order to reduce a potential focus of pressure.^{16, 17}

Appearance of the nails should also be noted. If there are nails that are incurvated or ingrown, these could be a potential area for skin breakdown and possible infection. Other nail issues to be aware of are onychomycosis (fungal nails), dystrophic nails, atrophy or hypertrophy, or paronychia (infected ingrown nail), as all can be potential problems.

Evaluation for any ulceration to the foot or lower leg should be assessed. Important

characteristics of ulcers are depth, size, presence of fibrotic or granulation tissue, location, and whether or not the area appears to be infected.

Anatomy of occlusive disease – vascular examination

For decades, clinicians incorrectly believed that ischemia in diabetes was due to microvascular occlusion of arterioles, so-called small vessel disease.¹⁸ However, this assumption has been disproven by subsequent study.^{19,20} Diabetic vascular disease is a macrovascular phenomenon, commonly affecting infrapopliteal arteries with calcified stenoses and occlusions. More than 90% of patients have sparing of at least one major artery at the ankle level. The peroneal artery is often the last infrapopliteal artery to occlude; it provides blood flow to the foot through anterior and posterior perforating branches to the tibial arteries. Bypass to an infrapopliteal artery usually provides adequate blood flow to the foot, although some patients appear to have more compartmentalized pedal flow. Some patients with heel ulcers remain slow to heal

after dorsalis pedis artery bypass, suggesting inadequate pedal circulation.²¹ Thus, if possible, patients with ischemic ulcers should preferentially receive a bypass to the arterial bed directly supplying the ulcer; this axiom is especially pertinent to patients with large heel ulcers.

Prediction of wound healing: assessment of perfusion

Pedal blood flow should be assessed before any surgical intervention on the diabetic foot. Absence of pedal pulses, dependent rubor, pallor on elevation, and loss of hair are clinical signs of advanced peripheral artery disease. If there is concern for ischemia, noninvasive testing is an appropriate initial diagnostic choice. The ankle-brachial index (ABI), while nearly 100% specific for PAD in non-diabetics, can be falsely elevated (>1.3) in diabetic patients due to medial calcinosis of the affected arteries. More useful are the systolic toe pressure and the toe-brachial index, since digital arteries are seldom calcified in those with diabetes.²² Additional tests to assess foot perfusion include skin perfusion pressure,^{23,24} and transcutaneous oxygen pressure (TcP_{O₂}).²⁵⁻²⁷

Currently there is no single test or combination of tests that can always predict wound healing. Apelqvist and colleagues prospectively studied 314 consecutive patients with diabetic foot ulcers.²² Primary healing occurred in 85% of patients with a toe pressure greater than 45 mmHg, while only 36% of patients with a toe pressure of 45 mmHg or less healed without an amputation. No patients with an ankle pressure less than 40 mmHg healed primarily. Kalani and colleagues also prospectively studied 50 patients with diabetic foot ulcers over a 12-month period.²⁶ A toe pressure of at least 30 mmHg had a 15% sensitivity, 97% specificity, and 67% positive predictive

value for wound healing. In that same study, TcP_{O₂} was also evaluated; a TcP_{O₂} of at least 25 mmHg had an 85% sensitivity, 92% specificity, and 79% positive predictive value for wound healing. Likewise, Carter and colleagues reported that TcP_{O₂} measurements correlated significantly with the risk of major amputation, with a relative risk of 2.55 for a TcP_{O₂} of 20 mmHg or less and 2.22 for a TcP_{O₂} of 30 mmHg or less.²⁷ In addition, an ankle pressure of 50 mmHg or less had a 5.83 relative risk of major amputation. Skin perfusion pressure (SPP) has also been used to predict wound healing. Faris evaluated 61 diabetic subjects with wounds and found that only 5% healed with an SPP less than 40 mmHg, while 88% of patients healed with an SPP higher than 40 mmHg.²³ Yamada and colleagues studied 211 subjects, half of who were diabetic, and compared SPP to other noninvasive methods to predict wound healing. They found that SPP was superior to ankle pressure, toe pressure, or TcP_{O₂} for predicting wound healing. An SPP of 40 mmHg had a 72% sensitivity and 88% specificity for predicting wound healing.²⁴ Furthermore, the accuracy of prediction increased when a toe pressure greater than 30 mmHg was combined with SPP.

Arterial imaging

A number of techniques of arterial imaging are currently in use: arterial duplex scanning, computed tomographic angiography (CTA), magnetic resonance angiography (MRA), and digital subtraction arteriography (DSA). Duplex scanning is non-invasive and does not require administration of contrast. However calcification of the infrageniculate arteries can be problematic in many patients. Both CTA and MRA have the advantage of being noninvasive; however, both these studies are limited

in diabetic patients with impaired renal function. CTA requires a large bolus of iodinated contrast, and the gadolinium-based contrast used in MRA has been associated with nephrogenic systemic fibrosis.²⁸ In addition, MRA tends to overestimate the degree of arterial stenosis. Using selective catheterization techniques, DSA can produce high-quality images with low volumes of iso-osmolar contrast, thereby minimizing contrast-induced nephropathy. In addition, carbon dioxide can be selectively utilized as a ‘contrast’ agent; it is not nephrotoxic and quickly dissolves in blood before travelling to the lungs where it is readily expelled. DSA also has the advantage that angioplasty and

stenting, if appropriate, may be performed at the time of diagnostic arteriography (Figure 26.4).

Soft tissue imaging

Imaging studies should be conducted to evaluate any underlying bone or soft tissue deformity. The diabetic foot is prone to many common and uncommon infectious and non-infectious processes due to the combination of vascular and neurological impairments. Imaging studies may be difficult to interpret and may lack specificity; therefore, a ‘shotgun’ approach to imaging studies should be avoided. Appropriate imaging studies should be ordered to establish




FIGURE 26.4: 56 year-old man with diabetes, renal insufficiency (serum creatinine 0.180mmol/L), absent foot pulses and non-healing dorsal foot ulcer for 6 weeks. Angiography showed normal arteries to the trifurcation and severe tibial artery occlusive disease with a long stenosis in dominant posterior tibial artery. Angioplasty markedly improved circulation and the wound healed with debridement, negative pressure wound therapy, and subsequent split-thickness skin graft placement.

- a) long segment, proximal posterior tibial artery stenosis
- b) 8 cm long, 4 mm percutaneous transluminal angioplasty (PTA) of proximal posterior tibial artery stenosis
- c) excellent angiographic result after balloon angioplasty

or confirm a suspected diagnosis in order to properly manage the patient. For example, it is very difficult to differentiate acute Charcot arthropathy from osteomyelitis on plain radiographs. The reliability of imaging studies is diminished in the presence of arterial occlusive disease, Charcot arthropathy or after recent surgery or trauma.²⁹ A thorough history and physical examination and clinical overview by the treating physician must be correlated with the imaging studies in order to interpret them correctly.

Plain radiographs should be the initial study considered for patients that present with any signs or symptoms of foot problems. These studies help to identify osteomyelitis, fracture, dislocation, foreign bodies, soft tissue gas, arterial calcification as well as any other biomechanical or structural deformity. It should be noted that it might take time for acute osteomyelitis to be detected on plain film radiographs and serial radiographs or magnetic resonance imaging (MRI) should be considered if osteomyelitis is strongly suspected.

Computed tomography (CT) scans may be indicated if plain films fail to depict a suspected bone or joint deformity. CT offers higher anatomic detail and resolution in regards to bone and joints. 3-D CT reconstruction can be done to provide a 360-degree view and increased visualization of any suspected abnormality.

MRI is usually preferred over a CT scan for suspected osteomyelitis due to the increased resolution of the image. MRI scans also allow the physician to visualize the extent of the infection- osteomyelitis, deep abscess and septic joints, but also other soft tissue pathology such as tendon rupture.

Bone scans can also provide some useful data when evaluating the diabetic foot. Technetium-99 methylene diphosphonate (Tc-99 MDP) as well as indium-111 bone scans can be useful in determining the

presence of osteomyelitis. However, while bone scans and other scintigraphic techniques are certainly possible tools to employ, their lack of specificity often makes their specific utility problematic, particularly if used in isolation. Advanced imaging studies beyond plain radiographs should not be routine. Rather, they should only be obtained to answer specific clinical questions when the results will alter management (e.g. concern over deep space infection with equivocal clinical picture).

CLASSIFICATION SYSTEMS

Diabetes mellitus foot risk classification

Based on a thorough history and physical examination, each patient should then be classified and assigned to a specific foot risk category as outlined in Table 26.2a. These categories were designed to direct and expedite the referral process to the necessary specialist and should also serve as a guide for subsequent follow-up visits. Increased categorical levels are associated with increasing risk for ulceration, hospitalization, and amputation.

University of Texas wound classification system

While many wound classification systems exist, The University of Texas (UT) ulcer classification system was developed to provide a more uniform evaluation of diabetic foot wounds. Like other classification systems the UT wound classification system builds on the depth-ischemia classification however, the UT system also considers infection.³⁰ The presence of infection and ischemia has been found to be more strongly predictive of outcome than the wound depth alone.³¹ The UT system uses a 4 by 4 matrix (classes

A to D, wound depths 0 to 3) and evaluates 3 factors of ulceration, which include depth, infection, and peripheral arterial disease (PAD).³² The frequency and level of amputation increases in deeper wounds and in the presence of infection and PAD.³⁰ Regardless of which specific classification is used, the key factors of depth, infection and ischemia should generally be communicated in some form. This classification is listed in (Table 26.2b).

CLINICAL PROBLEMS AND PRINCIPLES OF MANAGEMENT

Ulceration

Initial presentation of the diabetic foot usually entails the presence of an open ulcer, located on the plantar aspect of a patient's foot. Most patients will not suspect an ulcer on the bottom of their foot until they, or a loved one, notices blood either on the floor after walking or on a sock. Advising the patient that ambulation is contraindicated with an open ulcer is often challenging especially if the patient is neuropathic, as they have lost the 'gift of pain.'³³ However, reduction of pressure to the foot is essential for treatment. By effectively off-loading the area, the risk of continued trauma and resultant infection is decreased.

Epidemiology and risk factors

Ulceration of the diabetic foot is one of the single most common problems for which medical assistance is sought in a diabetic individual. Up to 25% of patients with diabetes will have a foot ulceration during their lifetime.⁴ Remarkably, at least 50% of those ulcerations will become infected, and in 20% of those cases an amputation is required.³⁴ There are 81,000 major amputations performed on individuals with diabetes in the United States annually. Conservatively, 60% of all non-traumatic amputations

occur in the diabetic patient.³⁵ Studies have shown that after a major amputation the contralateral limb develops a serious lesion in 50% of cases.³⁶ The 5 year adjusted mortality rate after a major amputation of a limb is 46%;⁶ this is alarming and is higher than the mortality rate for many forms of cancer. It has also been shown in more than 85% of lower extremity amputations a wound was a critical aspect of the causal pathway.^{8,34,37,38} The cost of treating diabetic foot ulcers is also growing at a staggering pace, reaching nearly \$30 billion in the United States in 2007.³⁹

Offloading

Numerous products are available to assist in redistributing pressure over a larger unit area (off-loading) on the foot. Some examples include removable cast walkers, non-weight bearing casts with crutch/walker assist, wedge sandals (either forefoot or heel wedge), healing sandals with a multilaminar, multidurometer foot bed. However, the choice of modality should be chosen with respect to the patient's functional status. For example, if a patient presents with a plantar forefoot ulcer, a wedge shoe that does not allow the forefoot to bear weight would be an appropriate device. However, if the patient is not properly educated on use of the device and/or has issues with balance, the offloading modality could cause the patient be unstable when walking. In regards to diabetic shoes, whether custom-made or off the shelf, it is important to keep in mind one key fact. While diabetic shoes are effective in preventing ulcerations, they are (in general) not very effective in healing them.

For many years the gold standard in off-loading an ulceration on the foot has been the total contact cast (TCC).⁴⁰ This fully weight-bearing cast consists of a multiple

layers of both fiberglass and plaster with minimal padding. When applied properly, the TCC allows the patient to be ambulatory. The TCC redirects pressure from the bottom of the foot, which is then redistributed over the bottom of the entire foot and up the cast. Some disadvantages of using a TCC is the time it takes to apply, the bulkiness for the patient, and the fact that the patient must wear the cast for 1 week intervals requiring weekly visits to the clinic. Newer TCC variants have reduced the time required for application of a traditional device whilst retaining many of the desirable therapeutic characteristics. An example of newer TCC variants can be seen in Figure 26.5.

Recent studies have evaluated the use of a removable cast walker rendered irremovable. This technique has been termed the ‘instant total contact cast (iTCC).’ This can be fabricated by simply adding a layer of fiberglass, cohesive bandage, or plaster

around the leg portion (Figure 26.6). The iTCC has proven to be an effective and easy offloading device that ensures patient adherence.⁴¹

In many instances, proper off-loading may be all that is necessary to achieve wound healing. However, if wound healing fails in the midst of proper off-loading, adequate blood flow, and satisfactory nutritional status, surgical intervention may be warranted.

Non-vascular surgical treatment

Surgical management of the diabetic lower extremity can be a challenging and frustrating task, but can be ultimately rewarding both to the physician and patient upon healing of an ulcer and correction of the underlying cause of the deformity. Surgery in the absence of critical limb ischemia is based on three fundamental principles: presence or absence of neuropathy (LOPS),



FIGURE 26.5: Anterior and lateral view of cast boot, which allows ambulation.



FIGURE 26.6: Example of an instant total contact cast (iTCC) with fiberglass wrapped around the leg portion, of an off-loading walking boot, to make it irremovable.

presence or absence of an open wound, and presence or absence of acute limb-threatening infection.⁴²

A classification system has been developed outlining non-vascular surgical treatment of patients with diabetes and has been divided into four categories and highlighted in Table 26.4 and is based on indications and perceived risk.^{42,43}

Class I: Elective

The goal of elective surgery is to reduce or eliminate any pain associated with a particular deformity and improve function.⁴² Examples of these deformities include bunions, hammertoes and bone spurs, all in patients without peripheral neuropathy and with a low chance for ulceration. Basically any type of reconstructive surgical procedure can fall into this category with the exception of an amputation. Rarely are amputations done as an elective procedure. Only in the case of severe deformity or instability from a previous injury or surgical procedure, will an amputation be considered. Assuming good glycemic control, patients grouped to this class are not at any increased risk for the development of complications than corresponding patients without diabetes.⁴³

Class II: Prophylactic

Procedures in this class are indicated to alleviate a deformity in a patient who is neuropathic however does not have the presence of an ulcer.⁴² The goal of prophylactic surgery is to reduce the plantar sheer and vertical stresses. Many procedures for prophylactic surgery would be considered elective if the patient did not suffer from neuropathy. Several examples of procedures in this class include a Charcot foot reconstruction, a metatarsal head resection, a Keller arthroplasty, an Achilles tendon lengthening or a hammertoe repair.

Class III: Curative

Curative surgery often is identical to prophylactic surgery with the exception that procedures in this class are designed to speed the healing rate of an open wound but also to eliminate any potential recurrence of the ulceration.⁴² Surgical procedures frequently utilized in this category may include exostectomy, digital arthroplasty, sesamoidectomy, single or multiple metatarsal head resection, joint resection or partial calcanectomy as well as Achilles tendon lengthening. Some surgeons may also elect to combine a plastic surgical flap and/or skin graft to help expedite healing.

Class IV: Emergency (Urgent)

Urgent procedures are performed to limit the spread of acute, limb and potentially life-threatening infection. Most often these procedures are done in the presence of significant ischemia. They require the removal of all infected and necrotic tissue to the level of viable soft tissue and bone and usually involve some level of amputation. When at all possible these procedures should be performed to allow for maximum amount of function to the extremity to be maintained.

With respect to any of the above classifications it is best to evaluate the vascular status of the patient to consider the necessity of any prior or subsequent arterial procedure that may be needed.⁴²

Post-operative management

The management of the diabetic foot patient in the post-operative setting is much the same as a patient without diabetes. Adequate pain control, rest, elevation of the extremity and proper dietary intake are all recommended. One key difference is the timeframe for protected weightbearing or complete non-weightbearing. It is often

stated that diabetics require twice the healing time as a non-diabetic. That means that if a simple bunionectomy in a non-diabetic requires 4 weeks of protected weightbearing, the same procedure in a diabetic may require 6-8 weeks of protected weightbearing. The same can be said for a procedure requiring non-weightbearing. Most surgical procedures done for class 1–3 can be managed with protected weightbearing.⁴³ Most class 4 procedures will require some period of non-weightbearing or protection. The same can be said for any type of surgical implant or skin closure technique. For example, leaving skin sutures in place for an additional 1–2 weeks is advantageous over early removal to allow for the tissue to heal.

Surgical and non-surgical complications in this patient population are to be expected. Joint dislocation, bone fracture, surgical incision dehiscence, new ulceration or re-ulceration, and infection are all commonplace, not infrequently leading to re-hospitalization. Proper management by use of off-loading, local wound care, antibiotics and patient education will all be beneficial when dealing with any potential complication. It should also be kept in mind that not all diabetic foot complications can

be prevented, but all can be adequately managed.

Infections

The Infectious Diseases Society of America (IDSA) has produced a classification system for diabetic foot infections, which is based on clinical signs and symptoms (Table 26.5). The IDSA divides infections into four categories, uninfected, mild, moderate, and severe.⁴⁴ These guidelines and classification system has become a reliable clinical predictor of the outcome of a diabetic foot infection.⁴⁵ It is important that initial antibiotic therapy cover the broad range of potential aetiological organisms in the diabetic foot until targeted therapy can be instituted once appropriate cultures have been obtained.

Charcot arthropathy

Charcot arthropathy is defined as a progressive condition characterized by joint dislocation, pathologic fractures, and severe destruction of the pedal framework (Figure 26.7). It is typically seen individuals with neuropathy and can be easily confused with acute infection or osteomyelitis. A

TABLE 26.4: Classification of non-vascular Diabetic Foot Surgery

Class	Type	Definition
1	Elective	Procedure performed on patient with protective sensation intact to eliminate pain or to improve function
2	Prophylactic	Procedure performed on patient with protective sensation absent but no open wound to reduce deformity and reduce occurrence/recurrence
3	Curative	Procedure performed on patient with an open wound with the goal of promoting healing and reducing risk for recurrence
4	Emergency	Procedure performed with goal of limiting the spread of limb- or life-threatening infection

patient will often present with a red, hot, swollen extremity with no sign or history of ulcer or break in the skin (Figure 26.8). Usually all other constitutional signs of infection are absent and laboratory values are within normal limits.

Pedal manifestations of Charcot foot result in a debilitating deformity frequently leading to an amputation. While not well understood, several theories regarding the development of the disorder exist with many authors believing it is caused by a combination of the neurovascular and neurotraumatic theories. Neuropathy and trauma seem

to be the common event preceding the development of an acute Charcot foot. As a result of the trauma and associated autonomic neuropathy, blood flow to the foot increases causing osteopenia and weakening of the bony structure. Fracture is often associated with unrecognized injury or minor trauma that might otherwise appear innocuous.^{46,47} An unfortunate cycle continues as the patient ambulates, without pain, causing further destruction of the foot.

The initial diagnosis of acute Charcot is often clinically based on the characteristics listed above. It can become complicated as

a)



b)



FIGURE 26.7a & b: X-ray of acute Charcot arthropathy. This plain x-ray demonstrates degenerative changes in the tarso-metatarsal joints (Lis-franc joints) with joint space narrowing and subchondrial sclerosis, consistent with Charcot arthropathy. Also noted is bone destruction and pathological fracture of the proximal phalanx of the 4th toe, indicative of osteomyelitis of this bone.

a)



b)

**FIGURE 26.8:**

- a)** Anterior view of acute Charcot. Notice the erythema and edema to the forefoot
- b)** Lateral view of acute Charcot. Marked flattening of the medial arch with associated edema and erythema.

patients often present with a concomitant ulcer, which raises questions of possible osteomyelitis. Someone presenting with the previously mentioned characteristics and lack of an open ulcer are more pathognomonic of acute Charcot arthropathy. Routine laboratory values are often of little use in diagnosing Charcot. They are valuable, however, with respect to excluding potential infection. An elevated WCC with a left shift is often seen with acute infection and not with acute Charcot. Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level may also be elevated in acute infection but they often respond to any inflammatory process and thus are nonspecific. The most important diagnostic aid in determination of acute Charcot is the high index of clinical suspicion when a neuropathic patient presents with a deformed or swollen foot.

Treatment of Charcot consists of immediate immobilization and stress reduction. Most physicians would recommend strict non-weight bearing to the affected limb. However, this then subjects the contralateral extremity to increased pressure thereby predisposing it to repetitive stress and the potential for ulceration or even acute Charcot.⁴⁸ Nonetheless, non-weight bearing by means of a short leg plaster or fiberglass cast, or TCC remains the gold standard in the acute phase of the disease.⁴⁰

Following the initial period of off-loading, skin temperatures and edema of the affected extremity will decrease. At this point protected weight bearing is permitted, usually with some sort of assistive device. This can be achieved through use of a Charcot restraint orthotic walker (CROW) (Figure 26.9), total contact cast, fixed ankle walker, bivalved casts or patellar tendon-

bearing braces, to name a few. The average time of rest and immobilization in a patient that has undergone an acute Charcot event is 4 to 6 months before returning to permanent and proper footwear.

If offloading is unsuccessful or if the deformity is unstable, reconstructive surgery may be considered. The goal of surgical intervention in the Charcot foot is to provide a stable, plantigrade foot that may be appropriately accommodated with proper shoe gear.⁴⁹ Most surgical interventions consist of an exostectomy for prominent plantar bony prominences or 'rocker-bottom' deformities that cause ulcerations and could lead to potential infection.⁵⁰ Other, more complex procedures such as arthrodesis of the midfoot and hindfoot, use of external fixation, and intramedullary nail have also been used in the latent stage of the Charcot disease process.



FIGURE 26.9: Charcot Restraint Orthotic Walker (CROW) boot. A patient is able to ambulate with this device once the acute phase has passed.

PREVENTION

Diabetic foot care requires an interdisciplinary team approach given the progressive nature of the disease in the foot. It is unlikely that one individual medical or surgical specialty is able to manage all aspects of diabetic lower extremity disease and appropriately manage these patients. Recent evidence suggests a reduction in major amputation rates following the development of an interdisciplinary approach to limb salvage.⁵¹ The components of a limb salvage team are predicated on the pathology at presentation. The core of the team typically starts with clinicians caring for the structural aspects of the foot (Podiatrists), along with clinicians caring for the vascular integrity of the lower extremity (Vascular Surgeons). Other specialties of the team, to add a more comprehensive care model may include Endocrinology, Infectious Diseases, Orthopaedic surgery, Physiotherapy, Plastic Surgery, Nursing and Orthotics/ Prosthetics.

Vasculopathy and neuropathy are two major contributors to diabetic foot disease and subsequent ulceration. Therefore, appropriate utilization of an interdisciplinary team approach, as stated above, will help to address the varying factors associated with lower extremity ulceration and reduce amputation. A diabetic rapid response acute foot team has been proposed in an effort to combine the knowledge of certain specialties to promote limb salvage.⁵² This is an interdisciplinary team model whose core involves the ability to rapidly diagnose and provide treatment to patients with lower-extremity complications of diabetes, utilizing seven basic skill sets (Table 26.6). At the forefront of the team are members from podiatry (Toe) and members from vascular surgery (Flow). These specialties, with adjunctive teams added as necessary,

combine to collectively possess the ability to perform the 7 essential skills, stated above, to be effective in promoting limb salvage. This model has been effective at the University of Arizona's Southern Arizona Limb Salvage Alliance (SALSA) in which the Vascular Surgery/Podiatry team approach has been able to significantly reduce the number of

major diabetes-associated lower-extremity amputations as well as provide a framework for prevention of diabetic ulcers. In fact, abundant data suggest that establishing such comprehensive diabetic foot care teams can significantly reduce the incidence of major amputation in both community and academic hospital settings.⁵³

TABLE 26.5: Infectious Diseases Society of America (IDSA) Diabetic Foot Infection Classification

Clinical Presentation	IDSA Infection Severity	Threatened Limb Class
Wound without inflammation or purulence	Uninfected	Not applicable
Presence of >2 manifestations of inflammation, cellulitis <2cm surrounding ulcer, no systemic symptoms of infection	Mild Infection	Non-limb threatening
Presence of infection with >2 cm of surrounding cellulitis; any infection with presence of gangrene, abscess, deep tissue involvement or gas in tissue; no systemic signs/symptoms of infection	Moderate Infection	Limb threatening
Presence of infection as above with the presence of systemic signs or symptoms	Severe Infection	Life and limb threatening

TABLE 26.6: Seven Essential Skills of a Diabetic Rapid Response Acute Foot Care Team (DRRAFT).

1. Ability to perform hemodynamic and anatomic vascular assessment with revascularization
2. Ability to perform a neurologic assessment
3. Ability to perform site-appropriate culture technique
4. Ability to perform wound assessment and staging/grading of infection and ischemia
5. Ability to perform site-specific bedside and intraoperative incision and debridement
6. Ability to initiate and modify culture-specific and patient-appropriate antibiotic therapy
7. Ability to perform appropriate postoperative monitoring to reduce risks of reulceration and infection

CONCLUSION

Treating the diabetic foot, but moreover the patient with diabetes, is an extremely challenging yet rewarding experience. As the incidence continues to grow worldwide the likelihood of people with diabetes constituting a significant proportion of a vascular and podiatric surgical practice is quite high. Common, seemingly trivial foot problems such as calluses, corns, ingrown nails, and dry scaly skin, may provide sufficient trauma to develop into limb-threatening problems. Early recognition and diagnosis of these factors combined with aggressive preventive measures and a multidisciplinary team approach will all be beneficial in the treatment of the diabetic foot with the ultimate goal of amputation reduction and prevention.


REFERENCES

1. Centers for Disease Control & Prevention – *National Diabetes Fact Sheet: General Information & National Estimates on Diabetes in the United States*. Atlanta, GA: Centers for Disease Control & Prevention; 2008.
2. World Health Organization – *Diabetes Fact Sheet, No 312*. Geneva: World Health Organization; 2009.
3. Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. *Diabetes Res Clin Pract* Jan; **87**(1):2–3.
4. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA* Jan 12 2005; **293**(2): 217–228.
5. Bharara M, Mills JL, Suresh K, Rilo HL, Armstrong DG. Diabetes and landmine-related amputations: a call to arms to save limbs. *Int Wound J* Feb 2009; **6**(1): 2–3.
6. Armstrong DG WJ, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? *Int Wound J* 2007; **4**: 286–287.
7. Rogers LC, Lavery LA, Armstrong DG. The Right To Bear Legs: An Amendment to Healthcare. How Preventing Amputations Can Save Billions for the US Health-care System *J Amer Podiatr Med Assn* 2008; **98**(2): 166–168.
8. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. *Diabetes Care* Jun 2006; **29**(6): 1288–1293.
9. Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. *J Foot Ankle Surg* 2000; **39**(5 Suppl): S1–60.
10. Armstrong DG, Stacpoole-Shea S, Nguyen HC, Harkless LB. Lengthening of the Achilles Tendon in Diabetic Patients Who Are at High Risk for Ulceration of the Foot. *J Bone Joint Surg (Am)* 1999; **81A**: 535–538.
11. Giacomozzi C, D’Ambrogi E, Uccioli L, Macellari V. Does the thickening of Achilles tendon and plantar fascia contribute to the alteration of diabetic foot loading? *Clin Biomech (Bristol, Avon)* Jun 2005; **20**(5): 532–539.
12. Grant WP, Foreman EJ, Wilson AS, Jacobus DA, Kukla RM. Evaluation of Young’s modulus in Achilles tendons with diabetic neuroarthropathy. *J Am Podiatr Med Assoc* May–Jun 2005; **95**(3): 242–246.
13. Rogers LC, Armstrong DG. Diabetic Foot Ulcers: Podiatry Care. In: Cronenwitt J, ed. *Rutherford Vascular*

- Surgery*. 7th ed. Amsterdam: Elsevier; 2009.
14. Boulton AJ, Armstrong DG, Albert SE, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. *Diabetes Care* Aug 2008; **31**(8): 1679–1685.
 15. Armstrong DG LL, Quebedeaux TL, et al. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. *Arch Intern Med* 1998; **158**:289–292.
 16. Pataky Z, Golay A, Faravel L, et al. The impact of callosities on the magnitude and duration of plantar pressure in patients with diabetes mellitus. A callus may cause 18,600 kilograms of excess plantar pressure per day. *Diabetes Metab* 2002; **28**(5): 356–361.
 17. Pitei DL, Foster A, Edmonds M. The effect of regular callus removal on foot pressures. *J Foot Ankle Surg*. 1999; **38**(4): 251–255; discussion 306.
 18. Goldenberg S, Alex M, Joshi RA, Blumenthal HT. Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. *Diabetes* Jul–Aug 1959; **8**(4): 261–273.
 19. Strandness DE, Jr., Priest RE, Gibbons GE. Combined Clinical and Pathologic Study of Diabetic and Nondiabetic Peripheral Arterial Disease. *Diabetes* Jul–Aug 1964; **13**: 366–372.
 20. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. *N Engl J Med* Dec 20 1984; **311**(25): 1615–1619.
 21. Berceci SA, Chan AK, Pomposelli FB, Jr., et al. Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. *J Vasc Surg* Sep 1999; **30**(3): 499–508.
 22. Apelqvist J, Castenfors J, Larsson J, Stenstrom A, Agardh CD. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer. *Diabetes Care* Jun 1989; **12**(6): 373–378.
 23. Faris I, Duncan H. Skin perfusion pressure in the prediction of healing in diabetic patients with ulcers or gangrene of the foot. *J Vasc Surg* Jul 1985; **2**(4): 536–540.
 24. Yamada T, Ohta T, Ishibashi H, et al. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs – comparison with other noninvasive diagnostic methods. *J Vasc Surg* Feb 2008; **47**(2): 318–323.
 25. Hauser CJ, Klein SR, Mehringer CM, Appel P, Shoemaker WC. Superiority of transcutaneous oximetry in noninvasive vascular diagnosis in patients with diabetes. *Arch Surg* Jun 1984; **119**(6): 690–694.
 26. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. *Diabetes Care* Jan 1999; **22**(1): 147–151.
 27. Carter SA, Tate RB. The relationship of the transcutaneous oxygen tension, pulse waves and systolic pressures to the risk for limb amputation in patients with peripheral arterial disease and skin ulcers or gangrene. *Int Angiol* Mar 2006; **25**(1): 67–72.
 28. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a

- report of 29 cases. *AJR Am J Roentgenol* Mar 2008; **190**(3): 736–741.
29. Belkin M, Welch HJ, Mackey WC, O'Donnell TF, Jr. Clinical and hemodynamic results of bypass to isolated tibial artery segments for ischemic ulceration of the foot. *Am J Surg* Sep 1992; **164**(3): 281–284; discussion 284–285.
 30. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. *Diabetes Care* May 1998; **21**(5): 855–859.
 31. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. *Diabetes Care* Jan 2001; **24**(1): 84–88.
 32. Andros GL, L. Diabetic Foot Ulcers. In: Jack Cronenwett K, Wayne Johnston, ed. *Rutherford's Vascular Surgery* Vol 2. Seventh ed: Saunders Elsevier; 2010 1735–1746.
 33. Brand PW YP. *The Gift of Pain*. Grand Rapids, Zondervan 1997.
 34. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. *Diabetes Care* May 2003; **26**(5): 1435–1438.
 35. DHHS. *National Diabetes Statistics Factsheet: general Information & National Estimates on Diabetes in the United States*. Bethesda: US Department of Health & Human Services; 2004.
 36. Goldner MG. The fate of the second leg in the diabetic amputee. *Diabetes* Mar–Apr 1960; **9**:100–103.
 37. Lavery LA, Peters EJ, Williams JR, Murdoch DP, Hudson A, Lavery DC. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. *Diabetes Care* Jan 2008; **31**(1): 154–156.
 38. Lavery LA, Wunderlich RP, Tredwell JL. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. *Diabetes Res Clin Pract* Oct 2005; **70**(1): 31–37.
 39. Rogers LC, Lavery LA, Armstrong DG. The right to bear legs – an amendment to healthcare: how preventing amputations can save billions for the US Health-care System. *J Am Podiatr Med Assoc* Mar–Apr 2008; **98**(2): 166–168.
 40. Armstrong DG, Stacpoole-Shea S. Total contact casts and removable cast walkers. Mitigation of plantar heel pressure. *J Am Podiatr Med Assoc* Jan 1999; **89**(1): 50–53.
 41. Wu SC, Crews RT, Armstrong DG. The pivotal role of offloading in the management of neuropathic foot ulceration. *Curr Diab Rep* Dec 2005; **5**(6): 423–429.
 42. Armstrong DG, Frykberg RG. Classifying diabetic foot surgery: toward a rational definition. *Diabet Med* Apr 2003; **20**(4): 329–331.
 43. Armstrong DG LL, Frykberg RG, et al. Validation of a diabetic foot surgery classification. *Int Wound J* 2006; **3**: 240–246.
 44. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of

- diabetic foot infections. *Clin Infect Dis* Oct 1 2004; **39**(7): 885–910.
45. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. *Clin Infect Dis* Feb 15 2007; **44**(4): 562–565.
 46. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). *J Foot Ankle Surg* Sep–Oct 2006; **45**(5 Suppl): S1–66.
 47. Armstrong DG LL, ed. *Clinical Care of the Diabetic Foot*. Alexandria, VA: American Diabetes Association Press; 2005.
 48. Armstrong DG, Liswood PJ, Todd WF. Contralateral limb during total contact casting. A dynamic pressure and thermometric analysis. *J Am Podiatr Med Assoc* Dec 1995; **85**(12): 733–737.
 49. Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. *J Am Podiatr Med Assoc* Jun 1997; **87**(6): 272–278.
 50. Catanzariti AR, Mendicino R, Haverstock B. Ostectomy for diabetic neuroarthropathy involving the midfoot. *J Foot Ankle Surg* Sep–Oct 2000; **39**(5): 291–300.
 51. Rogers LC, Andros G, Caporusso J, Harkless LB, Mills JL, Sr., Armstrong DG. Toe and flow: essential components and structure of the amputation prevention team. *J Am Podiatr Med Assoc* Sep–Oct 2010; **100**(5): 342–348.
 52. Fitzgerald RH, Mills JL, Joseph W, Armstrong DG. The diabetic rapid response acute foot team: 7 essential skills for targeted limb salvage. *Eplasty* 2009; **9**:15.
 53. Rogers LC, Andros G, Caporusso J, Harkless LB, Mills JL, Sr., Armstrong DG. Toe and flow: essential components and structure of the amputation prevention team. *J Vasc Surg* Sep 2010; **52**(3 Suppl): 23S–27S.



Cover diagram by David Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

Chapter 1: Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press